Qatar Investment Authority filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 2,804,360 shares of common stock in Iambic Therapeutics, Inc., representing 5.8% of the class as of October 15, 2026.
Key Highlights
- Beneficial owner: Qatar Investment Authority reported beneficial ownership of 2,804,360 shares of Iambic Therapeutics common stock (par value $0.001).
- Percent of class: The 2,804,360 shares represent 5.8% of the outstanding class, according to the filing.
- Sole voting and dispositive power: Qatar Investment Authority holds sole voting power and sole dispositive power over all 2,804,360 shares, with no shared voting or dispositive power reported.
- Acquiring subsidiary: The filing identifies Q Healthcare Holding LLC as the wholly owned subsidiary of Qatar Investment Authority that acquired the securities.
- Triggering event: The date of the event requiring the filing was October 15, 2026.
- Certifying signatory: Mohammed Fahad Al Khulaifi, Head of Compliance and Governance, signed the filing on behalf of Qatar Investment Authority.
Qatar Investment Authority's Ownership Position in Iambic Therapeutics
According to the Schedule 13G filed November 9, 2026, Qatar Investment Authority, a sovereign entity organized in Qatar, disclosed a 5.8% beneficial ownership stake in Iambic Therapeutics, Inc. (CUSIP: 45076A101). The filing states that the triggering event occurred on October 15, 2026. Iambic Therapeutics is headquartered at 5627 Oberlin Drive, Suite 120, San Diego, California, 92121, according to the filing.
The filing reports that Qatar Investment Authority holds sole voting power and sole dispositive power over all 2,804,360 shares, with zero shares subject to shared voting or shared dispositive power. The filing further discloses that Q Healthcare Holding LLC, identified as a wholly owned subsidiary of Qatar Investment Authority, is the entity that directly acquired the securities being reported.
In the filing's Item 10 certification, Qatar Investment Authority states that "the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11." The filing was signed by Mohammed Fahad Al Khulaifi, Head of Compliance and Governance, on November 9, 2026.
What Was Disclosed
Qatar Investment Authority, acting through its wholly owned subsidiary Q Healthcare Holding LLC, disclosed beneficial ownership of 2,804,360 shares of Iambic Therapeutics common stock, equal to 5.8% of the class, with all voting and dispositive power held solely by Qatar Investment Authority.




Please wait processing your request...